NovP
Desconocido
MEL-PLEX: Exploiting MELanoma disease comPLEXity to address European research training needs in translational...
NOVARTIS PHARMA GMBH
participó en un
H2020:
H2020-MSCA-ITN-2014
Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous a...
2014-12-16 - 2018-11-30 | Financiado
2014-12-16 - 2018-11-30 | Financiado
TARGETAMD: Transposon based targeted ex vivo gene therapy to treat age related macular degeneration AMD
NOVARTIS PHARMA GMBH
participó en un
FP7:
Age-related Macular Degeneration (AMD), a neurodegenerative disease of the retina, is a major cause of blindness in elderly people. Due to t...
Financiado
Financiado
* No se disponen de datos de la empresa actual.